Allogene Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018
Net Income	-293.56	-327.27	-340.41	-182.05	-316.38	-184.59	Upgrade
Depreciation & Amortization	14.25	14.2	14.3	10.45	7.44	4.42	Upgrade
Share-Based Compensation	59.11	65.95	83.6	80.82	65.26	46.06	Upgrade
Other Operating Activities	-6.78	9.38	22	-94.03	128.59	-3.24	Upgrade
Operating Cash Flow	-226.99	-237.73	-220.52	-184.81	-115.09	-137.35	Upgrade
Capital Expenditures	-0.49	-1.52	-5.19	-21.45	-65.96	-50.79	Upgrade
Change in Investments	72.98	164.81	111.35	185.1	-439.17	214.88	Upgrade
Investing Cash Flow	72.49	163.29	106.16	163.66	-505.12	164.08	Upgrade
Share Issuance / Repurchase	95.61	95.7	2.95	11.96	633.59	58.96	Upgrade
Financing Cash Flow	95.61	95.7	2.95	11.96	633.59	58.96	Upgrade
Net Cash Flow	-58.89	21.25	-111.41	-9.19	13.38	85.69	Upgrade
Free Cash Flow	-227.48	-239.25	-225.71	-206.26	-181.05	-188.14	Upgrade
Free Cash Flow Margin	-349972.31%	-251841.05%	-144685.90%	-180.79%	-	-	Upgrade
Free Cash Flow Per Share	-1.34	-1.52	-1.58	-1.52	-1.50	-1.86	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).